Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2

Show full item record



Permalink

http://hdl.handle.net/10138/333012

Citation

Wang , S , Wannasarit , S , Figueiredo , P , Molinaro , G , Ding , Y , Correia , A , Casettari , L , Wiwattanapatapee , R , Hirvonen , J , Liu , D , Li , W & Santos , H A 2021 , ' Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2 ' , Advanced Therapeutics , vol. 4 , no. 1 , 2000058 . https://doi.org/10.1002/adtp.202000058

Title: Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2
Author: Wang, Shiqi; Wannasarit, Saowanee; Figueiredo, Patricia; Molinaro, Giuseppina; Ding, Yaping; Correia, Alexandra; Casettari, Luca; Wiwattanapatapee, Ruedeekorn; Hirvonen, Jouni; Liu, Dongfei; Li, Wei; Santos, Hélder A.
Contributor organization: Nanomedicines and Biomedical Engineering
Division of Pharmaceutical Chemistry and Technology
Divisions of Faculty of Pharmacy
Drug Research Program
Jouni Hirvonen / Principal Investigator
Helsinki Institute of Life Science HiLIFE
Helsinki One Health (HOH)
Date: 2021-01
Language: eng
Number of pages: 11
Belongs to series: Advanced Therapeutics
ISSN: 2366-3987
DOI: https://doi.org/10.1002/adtp.202000058
URI: http://hdl.handle.net/10138/333012
Abstract: In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.
Subject: ANTIGEN
ENHANCEMENT
INFLAMMATION
NANOPARTICLES
PEPTIDES
POLYMERS
drug delivery
endosomal escape
macrophage phenotypes
microfluidics
polydopamine
317 Pharmacy
221 Nano-technology
318 Medical biotechnology
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
adtp.202000058.pdf 1.737Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record